Literature DB >> 21088132

Lymphomas differ in their dependence on Epstein-Barr virus.

David T Vereide1, Bill Sugden.   

Abstract

Epstein-Barr virus (EBV) encodes oncogenic information and, oftentimes concomitant with host immunosuppression, gives rise to malignancies in all major categories of lymphoma defined by the World Health Organization. Here, we conditionally evicted the viral extrachromosomal genome from tumor cells in vitro to examine the role of EBV in different lymphomas, including Burkitt lymphoma (BL) and posttransplant lymphoproliferative disorder. Cells derived from 2 canonical BLs were found to have the least dependence on the virus; some required EBV to prevent the inefficient induction of apoptosis. In contrast, cells derived from a subset of BL, Wp-restricted BL, required EBV to block a robust apoptotic program that involves the up-regulation of the proapoptotic protein Bim. Wp-restricted BL cells also relied on the virus to promote efficient proliferation, a distinction that highlights the multiple contributions EBV makes to affect proliferation of its host cells. Like Wp-BL cells, posttransplant lymphoproliferative disorder cells depended on the virus to inhibit apoptosis. They furthermore required the virus to drive them out of G(1)/G(0). Together, these results reveal a graded dependence on EBV among tumor cells that directly correlates with the number of viral genes expressed in the tumor cell.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088132      PMCID: PMC3056644          DOI: 10.1182/blood-2010-05-285791

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.

Authors:  G J Babcock; D Hochberg; A D Thorley-Lawson
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

Review 2.  Programmed cell death: alive and well in the new millennium.

Authors:  S H Kaufmann; M O Hengartner
Journal:  Trends Cell Biol       Date:  2001-12       Impact factor: 20.808

3.  The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines.

Authors:  Zachary L Pratt; Malika Kuzembayeva; Srikumar Sengupta; Bill Sugden
Journal:  Virology       Date:  2009-02-12       Impact factor: 3.616

4.  The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim.

Authors:  Anthony L Desbien; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-17       Impact factor: 11.205

5.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

Authors:  H A Coller; C Grandori; P Tamayo; T Colbert; E S Lander; R N Eisenman; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

6.  Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice.

Authors:  Leonard D Shultz; Yoriko Saito; Yuho Najima; Satoshi Tanaka; Toshiki Ochi; Mariko Tomizawa; Takehiko Doi; Akiko Sone; Nahoko Suzuki; Hiroshi Fujiwara; Masaki Yasukawa; Fumihiko Ishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 7.  Action of Myc in vivo - proliferation and apoptosis.

Authors:  S Pelengaris; B Rudolph; T Littlewood
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

8.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.

Authors:  Gemma Kelly; Andrew Bell; Alan Rickinson
Journal:  Nat Med       Date:  2002-09-03       Impact factor: 53.440

10.  An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.

Authors:  Gemma L Kelly; Heather M Long; Julianna Stylianou; Wendy A Thomas; Alison Leese; Andrew I Bell; Georg W Bornkamm; Josef Mautner; Alan B Rickinson; Martin Rowe
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

View more
  43 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

Authors:  Robert E White; Patrick C Rämer; Kikkeri N Naresh; Sonja Meixlsperger; Laurie Pinaud; Cliona Rooney; Barbara Savoldo; Rita Coutinho; Csaba Bödör; John Gribben; Hazem A Ibrahim; Mark Bower; Jamie P Nourse; Maher K Gandhi; Jaap Middeldorp; Fathima Z Cader; Paul Murray; Christian Münz; Martin J Allday
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

3.  Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Authors:  Shi-Dong Ma; Ming-Han Tsai; James C Romero-Masters; Erik A Ranheim; Shane M Huebner; Jillian A Bristol; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.

Authors:  Troy E Messick; Garry R Smith; Samantha S Soldan; Mark E McDonnell; Julianna S Deakyne; Kimberly A Malecka; Lois Tolvinski; A Pieter J van den Heuvel; Bai-Wei Gu; Joel A Cassel; Donna H Tran; Benjamin R Wassermann; Yan Zhang; Venkata Velvadapu; Edward R Zartler; Pierre Busson; Allen B Reitz; Paul M Lieberman
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

5.  Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus.

Authors:  Rachele Bigi; Justin T Landis; Hyowon An; Carolina Caro-Vegas; Nancy Raab-Traub; Dirk P Dittmer
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-14       Impact factor: 11.205

6.  LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Authors:  Shi-Dong Ma; Xuequn Xu; Julie Plowshay; Erik A Ranheim; William J Burlingham; Jeffrey L Jensen; Fotis Asimakopoulos; Weihua Tang; Margaret L Gulley; Ethel Cesarman; Jenny E Gumperz; Shannon C Kenney
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

7.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

Review 8.  Replication of Epstein-Barr viral DNA.

Authors:  Wolfgang Hammerschmidt; Bill Sugden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

Review 9.  Oncogenic mechanisms in Burkitt lymphoma.

Authors:  Roland Schmitz; Michele Ceribelli; Stefania Pittaluga; George Wright; Louis M Staudt
Journal:  Cold Spring Harb Perspect Med       Date:  2014-02-01       Impact factor: 6.915

10.  Epstein-Barr virus maintains lymphomas via its miRNAs.

Authors:  D T Vereide; E Seto; Y-F Chiu; M Hayes; T Tagawa; A Grundhoff; W Hammerschmidt; B Sugden
Journal:  Oncogene       Date:  2013-03-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.